Investors

Investors 2018-02-05T09:29:16+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

ASX – New corporate presentation

Dimerix has a new corporate presentation that details some of the scientific and strategic activities for our lead program, DMX-200 for chronic kidney disease (CKD). The presentation can be downloaded here.

Quarterly Review – Q2 FY2018

Quarter highlights DMX-200 Phase 2a in Chronic Kidney Disease sub-group analysis was released in November showing compelling efficacy signals in the Diabetic Nephropathy sub-group. Trial data was presented at the ASN Kidney Week in New [...]

Results of Entitlement Offer

Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December [...]

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time). Funds raised are important for the commercialisation of DMX-200 [...]

Read More

Media Coverage

ASX – New corporate presentation

Dimerix has a new corporate presentation that details some of the scientific and strategic activities for our lead program, DMX-200 for chronic kidney disease (CKD). The presentation can be downloaded here.

Quarterly Review – Q2 FY2018

Quarter highlights DMX-200 Phase 2a in Chronic Kidney Disease sub-group analysis was released in November showing compelling efficacy signals in the Diabetic Nephropathy sub-group. Trial data was presented at the ASN Kidney Week in New [...]

Results of Entitlement Offer

Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December [...]

PharmaVentures Interview with Kathy Harrison

Last November, Adrian Dawkes of PharmaVentures interviewed Kathy Harrison, CEO of Dimerix. Kathy discusses the companies focus on developing new therapeutic treatments identified using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology (HIT), and the [...]

Read More

Analyst Reports

Baker Young DXB Flash Note November 2017

Read this here. 

Bioshares November 2017

View their report here. 

ASX Announcements – Baker Young Initiates Coverage of DXB

Baker Young Stockbrokers have initiated coverage of Dimerix Limited. The research report is available here: BY-DXB Research Report - Oct - Initiation of Coverage - BUY.

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

Read More

Stock Quote

View stock price: ASX Stock Price

Corporate Fact Sheet

Most recent fact sheet: February 2018

Email Alert

subscribe to news updates